SBIR/STTR Research Award
Development, Production and Testing of VLP based Respiratory Syncytial Virus (RSV
Award amount
$509,623Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TECHNOVAX INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- CQC1WKNLJC41
- Solicitation number
- PA13-088
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): The goal of this proposal is to develop a safe and efficacious virus-like particle (VLP) based-respiratory syncytial virus (RSV) vaccine to prevent the disease caused by this pathogen. The respiratory illnesses provokedby RSV in infants, children and the elderly are of global economical and public health impact. A recent worldwide estimate [5] indicates that over 33 million children under the age of five suffer RSV associated lower respiratory infections (ALRI) and at least 3 million are hospitalized and approximately 199,000 die of the disease each year. In the US, the CDC estimates that there are over 126,000 RSV associated pediatric hospitalizations at a cost of over 900 million per year. There is no vaccine currently licensed and treatments for the disease are limited; a prophylactic intervention relies on administering a neutralizing monoclonal (Synagis) to infants at risk of infection and to supportive care. A safe and effective vaccine would be the most desir
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Production and Testing of VLP-based RSV Vaccine
- Next-Generation Adenovirus Vaccine
- Universal VLP-Based Flu Vaccine:Broadly protective (universal) virus-like particle (VLP) based influenza vaccine that can neutralize a broad spectrum of influenza A virus subtypes.
- Next-Generation Adenovirus Vaccine
- Next Generation of Multivalent Adenovirus Vaccines Based on Novel Virus-Like Particle (VLP) Technology
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
9 SBIR/STTR records share this UEI (2005–2020). Reported award amounts total $10,022,344. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense